✦ LIBER ✦

M1782 Characteristics of HBeAg-Positive Patients with HBsAg Loss/Seroconversion Following Treatment with Tenofovir Disoproxil Fumarate (TDF)

✍ Scribed by Heathcote, Jenny; Germanidis, George; Dusheiko, Geoffrey M.; Jacobson, Ira M.; De Man, Robert A.; Nikolaidis, Paul; Marcellin, Patrick; Sorbel, Jeff; Anderson, Jane; Mondou, Elsa; Quinn, Joe; Rousseau, Franck

Book ID: 123441786
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 48 KB
Volume: 136
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(09)63856-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

909 CHARACTERISTICS OF HBeAg-POSITIVE PA

909 CHARACTERISTICS OF HBeAg-POSITIVE PATIENTS WITH HBsAg LOSS/SEROCONVERSION FOLLOWING TREATMENT WITH TENOFOVIR DISOPROXIL FUMARATE (TDF)

✍ E.J. Heathcote; G. Germanidis; G. Dusheiko; I. Jacobson; R. deMan; P. Nikolaidis 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 50 KB

1006 HBSAG KINETICS OF DECAY AND BASELIN

1006 HBSAG KINETICS OF DECAY AND BASELINE CHARACTERISTICS OF HBEAG-POSITIVE PATIENTS WITH CHRONIC HEPATITIS B FOLLOWING 3 YEARS OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT

✍ Gane, E.; Heathcote, E.J.; Marcellin, P.; Dusheiko, G.; Jacobson, I.; de Man, R. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Genotype and Baseline HBsAg Levels Are S

Genotype and Baseline HBsAg Levels Are Significantly Associated With HBeAg Seroconversion Following up to 4 Years of Tenofovir Disoproxil Fumarate Treatment

✍ Heathcote, E. Jenny ;Manns, Michael P. ;Mathurin, Philipe ;Ebrahimi, Ramin ;Ande 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 245 KB

715 BASELINE GENOTYPE AND HBSAG WERE FOU

715 BASELINE GENOTYPE AND HBSAG WERE FOUND TO HAVE SIGNIFICANT ASSOCIATION WITH HBEAG SEROCONVERSION FOLLOWING UP TO 4 YEARS OF TENOFOVIR DISOPROXIL FUMARATE TREATMENT

✍ J. Heathcote; M. Manns; P. Mathurin; R. Ebrahimi; J. Anderson; L. Lou; C. Ng 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 42 KB

20 THREE YEARS OF TENOFOVIR DISOPROXIL F

20 THREE YEARS OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT IN HBEAG-NEGATIVE AND POSITIVE PATIENTS WITH CHRONIC HEPATITIS B (STUDY 102 AND STUDY 103)

✍ M. Rizzetto; P. Marcellin; E.J. Heathcote; J. Sorbel; E. Mondou; J. Anderson; F. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 58 KB

925 SAFETY AND TOLERABILITY OF 96 WEEKS

925 SAFETY AND TOLERABILITY OF 96 WEEKS OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT IN HBeAg NEGATIVE AND POSITIVE PATIENTS INFECTED WITH CHRONIC HEPATITIS B (CHB)

✍ P. Marcellin; E.J. Heathcote; I. Jacobson; P. Mathurin; E. Gane; P. Buggisch; P. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 161 KB